UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

BMC psychiatry, 2021-05, Vol.21 (1), p.249-249, Article 249

2021

Volltextzugriff (PDF)

A real-world data analysis of electronic health records to investigate the associations of predominant negative symptoms with healthcare resource utilisation, costs and treatment patterns among patients with schizophrenia

BMJ open, 2024-07, Vol.14 (7), p.e084613

2024

Volltextzugriff (PDF)

Healthcare resource utilization and quality of life by cognitive impairment in patients with schizophrenia

Schizophrenia research. Cognition, 2022-06, Vol.28, p.100233-100233, Article 100233

2022

Volltextzugriff (PDF)

The Economic Burden of Schizophrenia in the United States

The journal of clinical psychiatry, 2022-11, Vol.83 (6)

2022

Volltextzugriff (PDF)

Buprenorphine transdermal system utilization

Postgraduate medicine, 2017-01, Vol.129 (1), p.81-86

2017

Volltextzugriff (PDF)

Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression

Journal of the American Academy of Child and Adolescent Psychiatry, 2022-02, Vol.61 (2), p.243-254

2022

Volltextzugriff (PDF)

The Incidence and Economic Burden of Extrapyramidal Symptoms in Patients with Schizophrenia Initiating Atypical Antipsychotics in a Commercially Insured Population

CNS spectrums, 2022-04, Vol.27 (2), p.228-228

2022

Volltextzugriff (PDF)

The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework

The journal of clinical psychiatry, 2023-08, Vol.84 (5)

2023

Volltextzugriff (PDF)

A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor

Advances in therapy, 2024-09, Vol.41 (9), p.3706-3721

2024

Volltextzugriff (PDF)

Real-World Outcomes Associated with Cognitive Impairment Among Patients with Schizophrenia

CNS spectrums, 2022-04, Vol.27 (2), p.254-254

2022

Volltextzugriff (PDF)

Healthcare Resource Use and Quality of Life Associated with Cognitive Impairment Among Patients with Schizophrenia

CNS spectrums, 2022-04, Vol.27 (2), p.227-227

2022

Volltextzugriff (PDF)

Assessing the Risk of Health, Social, and Fiscal Events in Schizophrenia According to Remission or Relapse Status Using Real World Data from a SCZ Survey in the US

CNS spectrums, 2022-04, Vol.27 (2), p.225-226

2022

Volltextzugriff (PDF)

The Economic Burden of Schizophrenia in the United States in 2019

CNS spectrums, 2022-04, Vol.27 (2), p.227-227

2022

Volltextzugriff (PDF)

Point-in-time survey of healthcare resource utilization, employment, quality of life and caregiver status by disease severity in patients with schizophrenia in the US

Current medical research and opinion, 2022-03, Vol.38 (3), p.469-478

2022

Volltextzugriff (PDF)

Psychiatric Inpatient Healthcare Resource Utilization and Treatment Patterns Among Patients With Predominant Negative Symptoms in Schizophrenia

CNS spectrums, 2023-04, Vol.28 (2), p.222-223

2023

Volltextzugriff (PDF)

Change in abuse diagnoses in patients prescribed oxycontin after its reformulation with abuse-deterrent properties

Drug and alcohol dependence, 2017-02, Vol.171, p.e97-e97

2017

Volltextzugriff (PDF)

Change in overdose/poisoning diagnoses in patients prescribed oxycontin after its reformulation with abuse-deterrent properties

Drug and alcohol dependence, 2017-02, Vol.171, p.e46-e46

2017

Volltextzugriff (PDF)

Changes in diagnosed addiction rates in patients prescribed opioids after introduction of OxyContin with abuse-deterrent properties

Drug and alcohol dependence, 2015-11, Vol.156, p.e48-e48

2015

Volltextzugriff (PDF)

Burden of EPS in commercial patients with schizophrenia initiating atypical antipsychotics

The American journal of managed care, 2022-09, Vol.28 (9), p.e315-e324

2022

Volltextzugriff (PDF)

4.38 A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF THE EFFICACY AND SAFETY OF ANTIPSYCHOTICS FOR DEPRESSION ASSOCIATED WITH BIPOLAR DISORDER IN YOUTH

Journal of the American Academy of Child and Adolescent Psychiatry, 2019-10, Vol.58 (10), p.S231-S232

2019

Volltextzugriff (PDF)

A rare presentation of perioperative myocardial infarction as a consequence of stent thrombosis in non-cardiac surgery

International journal of research in medical sciences, 2021-06, Vol.9 (7), p.2125

2021

Volltextzugriff (PDF)

The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population

Journal of medical economics, 2022-12, Vol.25 (1), p.87-98

2022

Volltextzugriff (PDF)

Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database study

Journal of medical economics, 2021-01, Vol.24 (1), p.1212-1220

2021

Volltextzugriff (PDF)

The Incidence and Economic Burden of Extrapyramidal Symptoms in Patients with Schizophrenia Treated with Atypical Antipsychotics

CNS spectrums, 2021-04, Vol.26 (2), p.168-169

2021

Volltextzugriff (PDF)

Comparison of the risk of opioid overdose among patients prescribed immediate-release and extended-release opioid analgesics

Drug and alcohol dependence, 2015-01, Vol.146, p.e251-e251

2015

Volltextzugriff (PDF)

1 – 25 von 32

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(29)
Mit Volltextzugriff
(25)

Publikationsform

Artikel
(32)

Sprache

Englisch
(32)
Japanisch
(1)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(16)
Science & Technology
(16)
Humans
(14)
Schizophrenia
(12)
Psychiatry
(11)
Abstracts
(7)
Antipsychotics
(7)
General & Internal Medicine
(6)
Medicine, General & Internal
(6)
Psychotropic Drugs
(6)
Schizophrenia - Epidemiology
(6)
Social Sciences
(6)
Retrospective Studies
(5)
United States
(5)
Adolescent
(4)
Aged
(4)
Antipsychotic Agents - Adverse Effects
(4)
Financial Stress
(4)
Medicare
(4)
Original Research
(4)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis

A real-world data analysis of electronic health records to investigate the associations of predominant negative symptoms with healthcare resource utilisation, costs and treatment patterns among patients with schizophrenia

Healthcare resource utilization and quality of life by cognitive impairment in patients with schizophrenia

The Economic Burden of Schizophrenia in the United States

Buprenorphine transdermal system utilization

Systematic Review and Network Meta-analysis: Efficacy and Safety of Second-Generation Antipsychotics in Youths With Bipolar Depression

The Incidence and Economic Burden of Extrapyramidal Symptoms in Patients with Schizophrenia Initiating Atypical Antipsychotics in a Commercially Insured Population

The Lifetime Burden of Schizophrenia as Estimated by a Government-Centric Fiscal Analytic Framework

A Real-World Comparison of Clinical Effectiveness in Patients with Rheumatoid Arthritis Treated with Upadacitinib, Tumor Necrosis Factor Inhibitors, and Other Advanced Therapies After Switching from an Initial Tumor Necrosis Factor Inhibitor

Real-World Outcomes Associated with Cognitive Impairment Among Patients with Schizophrenia

Healthcare Resource Use and Quality of Life Associated with Cognitive Impairment Among Patients with Schizophrenia

Assessing the Risk of Health, Social, and Fiscal Events in Schizophrenia According to Remission or Relapse Status Using Real World Data from a SCZ Survey in the US

The Economic Burden of Schizophrenia in the United States in 2019

Point-in-time survey of healthcare resource utilization, employment, quality of life and caregiver status by disease severity in patients with schizophrenia in the US

Psychiatric Inpatient Healthcare Resource Utilization and Treatment Patterns Among Patients With Predominant Negative Symptoms in Schizophrenia

Change in abuse diagnoses in patients prescribed oxycontin after its reformulation with abuse-deterrent properties

Change in overdose/poisoning diagnoses in patients prescribed oxycontin after its reformulation with abuse-deterrent properties

Changes in diagnosed addiction rates in patients prescribed opioids after introduction of OxyContin with abuse-deterrent properties

Burden of EPS in commercial patients with schizophrenia initiating atypical antipsychotics

4.38 A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS OF THE EFFICACY AND SAFETY OF ANTIPSYCHOTICS FOR DEPRESSION ASSOCIATED WITH BIPOLAR DISORDER IN YOUTH

A rare presentation of perioperative myocardial infarction as a consequence of stent thrombosis in non-cardiac surgery

The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population

Hospitalization risk in pediatric patients with bipolar disorder treated with lurasidone vs. other oral atypical antipsychotics: a real-world retrospective claims database study

The Incidence and Economic Burden of Extrapyramidal Symptoms in Patients with Schizophrenia Treated with Atypical Antipsychotics

Comparison of the risk of opioid overdose among patients prescribed immediate-release and extended-release opioid analgesics

Suchergebnisse filtern